Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study

PLoS Medicine

Volumn 15, Issue 6, 2018, Pages

  Verma, Amol A ^a,b   Khuu, Wayne ^c   Tadrous, Mina ^c,d   Gomes, Tara ^c,d,e   Mamdani, Muhammad M ^c,d,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Institute for Clinical and Evaluative Sciences   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; INDAPAMIDE; ANTIHYPERTENSIVE AGENT; THIAZIDE DIURETIC AGENT;

ACUTE HEART INFARCTION; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; COHORT ANALYSIS; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; POPULATION RESEARCH; PROPENSITY SCORE; RETROSPECTIVE STUDY; COMBINATION DRUG THERAPY; DOSE CALCULATION; DOSE RESPONSE; ONTARIO; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; ONTARIO; RETROSPECTIVE STUDIES; SODIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME;

EID: 85049506518     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002584     Document Type: Article

References (39)

1. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317: 165–182. doi: 10.1001/jama.2016.19043 pmid: 28097354
2. Forouzanfar MH, Afshin A, Alexander LT, Anderson HR, Bhutta ZA, Biryukov S, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388: 1659–1724. doi: 10.1016/S0140-6736(16)31679-8 pmid: 27733284
3. Gradman AH, Basile JN, Carter BL, Bakris GL, Combination therapy in hypertension. J Am Soc Hypertens. Elsevier Ltd; 2010;4: 90–98. doi: 10.1016/j.jash.2010.03.001 pmid: 20400053
4. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. JAMA. 2014;311: 507. doi: 10.1001/jama.2013.284427 pmid: 24352797
5. Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, et al. Hypertension Canada’s 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Can J Cardiol. Elsevier Inc.; 2017;33: 557–576. doi: 10.1016/j.cjca.2017.03.005 pmid: 28449828
6. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2017; HYP.0000000000000065. doi: 10.1161/HYP.0000000000000065 pmid: 29133356
7. Chalmers J, Arima H, Harrap S, Touyz RM, Park JB, Global survey of current practice in management of hypertension as reported by societies affiliated with the International Society of Hypertension. J Hypertens. 2013;31: 1043–8. doi: 10.1097/HJH.0b013e32835f7eef pmid: 23429664
8. Lauffenburger JC, Landon JE, Fischer MA, Effect of Combination Therapy on Adherence Among US Patients Initiating Therapy for Hypertension: a Cohort Study. J Gen Intern Med. 2017;32: 619–625. doi: 10.1007/s11606-016-3972-z pmid: 28050754
9. Schaffer AL, Pearson S-A, Buckley NA, How does prescribing for antihypertensive products stack up against guideline recommendations? An Australian population-based study (2006–2014). Br J Clin Pharmacol. 2016;82: 1134–1145. doi: 10.1111/bcp.13043 pmid: 27302475
10. Gupta AK, Arshad S, Poulter NR, Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents: A Meta-Analysis. Hypertension. 2010;55: 399–407. doi: 10.1161/HYPERTENSIONAHA.109.139816 pmid: 20026768
11. Buess D, Dieterle T, Leuppi JD, Zeller A, Martina B, Tschudi P, et al. [PP.39.07] Fixed-Dose Combinations of Antihypertensive Drugs May Not Improve Blood Pressure Control Compared to Free Drug Combinations–Findings from The Swiss Hypertension Cohort Study. J Hypertens. 2016;34: e355. doi: 10.1097/01.hjh.0000492382.81220.e4
12. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH, Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis. Am J Med. 2007;120: 713–719. doi: 10.1016/j.amjmed.2006.08.033 pmid: 17679131
13. Baser O, Andrews LM, Wang L, Xie L, Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy. J Med Econ. 2011;14: 576–583. doi: 10.3111/13696998.2011.596873 pmid: 21728914
14. Gautam CS, Saha L, Fixed dose drug combinations (FDCs): rational or irrational: a view point. Br J Clin Pharmacol. 2008;65: 795–796. doi: 10.1111/j.1365-2125.2007.03089.x pmid: 18294326
15. Angeli F, Reboldi G, Mazzotta G, Garofoli M, Ramundo E, Poltronieri C, et al. Fixed-Dose Combination Therapy in Hypertension. High Blood Press Cardiovasc Prev. 2012;19: 51–54. doi: 10.2165/11632070-000000000-00000 pmid: 22867089
16. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of Antihyperlipidemic Drugs—Do Rates Reported in Clinical Trials Reflect Rates in Primary Care Settings?N Engl J Med. 1995;332: 1125–1131. doi: 10.1056/NEJM199504273321703 pmid: 7700285
17. Levy AR, O’Brien BJ, Sellors C, Grootendorst P, Willison D, Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10: 67–71. pmid: 12879144
18. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006;354: 1352–61. doi: 10.1056/NEJMoa055191 pmid: 16510739
19. Dhalla IA, Gomes T, Yao Z, Nagge J, Persaud N, Hellings C, et al. Chlorthalidone Versus Hydrochlorothiazide for the Treatment of Hypertension in Older Adults. Ann Intern Med. 2013;158: 447. doi: 10.7326/0003-4819-158-6-201303190-00004 pmid: 23552325
20. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351: 543–551. doi: 10.1056/NEJMoa040135 pmid: 15295047
21. PROGRESS Collaborative GroupRandomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358: 1033–1041. doi: 10.1016/S0140-6736(01)06178-5 pmid: 11589932
22. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA, High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20: 512–22. doi: 10.1097/EDE.0b013e3181a663cc pmid: 19487948
23. Division of Pharmacoepidemiology and Pharmacoeconomics. Pharmacoepidemiology Toolbox including High-dimensional Propensity Score (hd-PS) Adjustment version 2 [Internet]. Available from: http://www.drugepi.org/dope-downloads/. [cited 31 May 2017].
24. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical Practice Guidelines for the Management of Hypertension in the Community. J Clin Hypertens. 2014;16: 14–26. doi: 10.1111/jch.12237 pmid: 24341872
25. Juurlink D, Preyra C, Croxford R, Chong A, Austin P, Tu J, et al. Canadian Institute for Health Information Discharge Abstract Database: A validation study. Inst Clin Eval Sci. 2006; 1–77.
26. Porter J, Mondor L, Kapral MK, Fang J, Hall RE, How Reliable Are Administrative Data for Capturing Stroke Patients and Their Care. Cerebrovasc Dis Extra. 2016;6: 96–106. doi: 10.1159/000449288 pmid: 27750249
27. Nguyen T-L, Collins GS, Spence J, Daurès J-P, Devereaux PJ, Landais P, et al. Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. BMC Med Res Methodol. 2017;17: 78. doi: 10.1186/s12874-017-0338-0 pmid: 28454568
28. Austin PC, The use of propensity score methods with survival or time-to-event outcomes: Reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33: 1242–1258. doi: 10.1002/sim.5984 pmid: 24122911
29. Osterberg L, Blaschke T, Adherence to Medication. N Engl J Med. 2005;353: 487–497. doi: 10.1056/NEJMra050100 pmid: 16079372
30. Schroeder K, Fahey T, Ebrahim S, How Can We Improve Adherence to Blood Pressure–Lowering Medication in Ambulatory Care?Arch Intern Med. 2004;164: 722. doi: 10.1001/archinte.164.7.722 pmid: 15078641
31. Webster R, Patel A, Selak V, Billot L, Bots ML, Brown A, et al. Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. Int J Cardiol. Netherlands; 2016;205: 147–156. doi: 10.1016/j.ijcard.2015.12.015 pmid: 26736090
32. Mazza A, Lenti S, Schiavon L, Sacco AP, Dell’Avvocata F, Rigatelli G, et al. Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control: From Clinical Trials to Clinical Practice. Adv Ther. 2017;34: 975–985. doi: 10.1007/s12325-017-0511-1 pmid: 28299716
33. Belsey JD, Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs individual component regimens. J Med Econ. 2012;15: 897–905. doi: 10.3111/13696998.2012.689792 pmid: 22548677
34. Fralick M, Kesselheim AS, Avorn J, Schneeweiss S, Use of Health Care Databases to Support Supplemental Indications of Approved Medications. JAMA Intern Med. 2017;2120: 1–9. doi: 10.1001/jamainternmed.2017.3919
35. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148: 16–29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17984484. pmid: 17984484
36. Li EC, Heran BS, Wright JM, Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014; CD009096. doi: 10.1002/14651858.CD009096.pub2 pmid: 25148386
37. Van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J. 2012;33: 2088–2097. doi: 10.1093/eurheartj/ehs075 pmid: 22511654
38. Lam WY, Fresco P, Medication Adherence Measures: An Overview. Biomed Res Int. Hindawi Publishing Corporation; 2015;2015. doi: 10.1155/2015/217047 pmid: 26539470
39. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310: 959–68. doi: 10.1001/jama.2013.184182 pmid: 24002282